|
Publications (limited out of 101 total)
|
|
|
|
|
2017Publications
Youn MY, Wang N, LaVasseur C, Bibikova E, Kam S, Glader B, Sakamoto KM*, and A. Narla*. Loss of FOXM1 promotes erythropoiesis through increased proliferation of erythroid progenitors. Haematologica, in press. *co-senior authors.
Wilkes MC, Repellin CE and Sakamoto KM. Beyond mRNA: The role of non-coding RNAs in normal and aberrant hematopoiesis. Mol Genet Metab. S1096-7192, 2017.
Sakamoto KM. Lost in translation: RP and GATA1 mutations in DBA. Commentary. Blood, 239:3048-3049, 2017.
Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, Smith M, Sakamoto KM.
Oncotarget. 2017 Dec 31;9(4):4301-4317. doi: 10.18632/oncotarget.23794. eCollection 2018 Jan 12. PMID: 29435104
|
2016Publications
Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo. François S, Sen N, Mitton B, Xiao X, Sakamoto KM, Arvin A.
J Virol. 2016 Sep 12;90(19):8686-97. doi: 10.1128/JVI.00920-16.
Small molecule screen for inhibitors of expression from canonical CREB response element-containing promoters.
Mitton B, Hsu K, Dutta R, Tiu BC, Cox N, McLure KG, Chae HD, Smith M, Eklund EA, Solow-Cordero DE, Sakamoto KM.
Oncotarget. 2016 Feb 23;7(8):8653-62. doi: 10.18632/oncotarget.7085.
Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells.
Mitton B, Chae HD, Hsu K, Dutta R, Aldana-Masangkay G, Ferrari R, Davis K, Tiu BC, Kaul A, Lacayo N, Dahl G, Xie F, Li BX, Breese MR, Landaw EM, Nolan G, Pellegrini M, Romanov S, Xiao X, Sakamoto KM. Leukemia. 2016 Jun 10. doi: 10.1038/leu.2016.139. [Epub ahead of print]
A Zebrafish Model of 5q-Syndrome Using CRISPR/Cas9 Targeting RPS14 Reveals a p53-Independent and p53-Dependent Mechanism of Erythroid Failure.
Ear J, Hsueh J, Nguyen M, Zhang Q, Sung V, Chopra R, Sakamoto KM, Lin S.
J Genet Genomics. 2016 May 20;43(5):307-18. doi: 10.1016/j.jgg.2016.03.007. Epub 2016 Apr 2.
CBP/p300 acetyltransferase activity in hematologic malignancies.
Dutta R, Tiu B, Sakamoto KM.
Mol Genet Metab. 2016 Jun 30. pii: S1096-7192(16)30122-6. doi: 10.1016/j.ymgme.2016.06.013. [Epub ahead of print] Review.
|
2015Publications
Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB, Narla A, Park JK, Lin S, Sakamoto KM.
Mol Genet Metab. 2015 Jul 20. pii: S1096-7192(15)30034-2. doi: 10.1016/j.ymgme.2015.07.004. [Epub ahead of print] Review.
Flow-induced protein kinase A-CREB pathway acts via BMP signaling to promote HSC emergence.
Kim PG, Nakano H, Das PP, Chen MJ, Rowe RG, Chou SS, Ross SJ, Sakamoto KM, Zon LI, Schlaeger TM, Orkin SH, Nakano A, Daley GQ.
J Exp Med. 2015 May 4;212(5):633-48. doi: 10.1084/jem.20141514. Epub 2015 Apr 13.
Replication factor C3 is a CREB target gene that regulates cell cycle progression through the modulation of chromatin loading of PCNA.
Chae HD, Mitton B, Lacayo NJ, Sakamoto KM.
Leukemia. 2015 Jun;29(6):1379-89. doi: 10.1038/leu.2014.350. Epub 2014 Dec 26.
|
2014Publications
TNF-mediated inflammation represses GATA1 and activates p38 MAP kinase in RPS19-deficient hematopoietic progenitors.
Bibikova E, Youn MY, Danilova N, Ono-Uruga Y, Konto-Ghiorghi Y, Ochoa R, Narla A, Glader B, Lin S, Sakamoto KM.
Blood. 2014 Dec 11;124(25):3791-8. doi: 10.1182/blood-2014-06-584656. Epub 2014 Sep 30.
PMID: 25270909 [PubMed - in process]
Letting microRNAs overcome resistance to chemotherapy in acute myeloid leukemia.
Sakamoto KM.
Leuk Lymphoma. 2014 Jul;55(7):1449-50. doi: 10.3109/10428194.2013.862244. Epub 2014 Jan 28. No abstract available.
PMID: 24206095 [PubMed - in process]
Reiss UM, Schwartz J, Sakamoto KM, Puthenveetil G, Ogawa M, Bedrosian, and RE Ware.
Efficacy and Safety of Eculizumab in Children and Adolescents with Paroxysmal Nocturnal
Hemoglobinuria. Pediatr Blood Cancer, April 29, 2014 [Epub ahead of print]>
Danilova N, Bibikova E, Covey TM, Nathanson D, Dimitrova E, Lindgren A, Glader B,
Radu CG, Sakamoto KM, and S Lin. The Role of DNA damage response in zebrafish and
cellular models of Diamond Blackfan Anemia. Disease Models and Mechanisms,
7:895-905, 2014.
|
2012Publications
MiR-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation.
Pigazzi M, Manara E, Bresolin S, Tregnago C, Beghin A, Baron E, Giarin E, Cho EC, Masetti R, Rao DS, Sakamoto KM, Basso G.
Haematologica. 2012 Oct 25. [Epub ahead of print]
PMID: 23100280 [PubMed - as supplied by publisher] Free Article
Blood. 2012 Jul 5;120(1):155-65. Epub 2012 May 24.
Sox4 cooperates with CREB in myeloid transformation.
Sandoval S, Kraus C, Cho EC, Cho M, Bies J, Manara E, Accordi B, Landaw EM, Wolff L, Pigazzi M, Sakamoto KM.
PMID: 22627767 [PubMed - in process] PMCID: PMC3390953 [Available on 2013/7/5
|
2011Publications
Crit Rev Oncog. 2011;16(1-2):37-46.
CREB and leukemogenesis.
Cho EC, Mitton B, Sakamoto KM.
PMID: 22150306 [PubMed - indexed for MEDLINE] PMCID: PMC3243968
Transplantation for congenital bone marrow failure syndromes.
Morimoto K, Moore TB, Schiller G, Sakamoto KM.
Bone Marrow Res. 2011;2011:849387.
The function of cyclic-adenosine monophosphate responsive element-binding protein in hematologic malignancies.
Mitton B, Cho EC, Aldana-Masangkay GI, Sakamoto KM.
Leuk Lymphoma. 2011 Nov;52(11):2057-63.
Editorial: granulopoiesis versus monopoiesis: a consequence of transcription factors dancing with the right partners.
Sakamoto KM.
J Leukoc Biol. 2011 Oct;90(4):637-8.
Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
Aldana-Masangkay GI, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Hsieh YT, Kim YM, Lomenick B, Okemoto K, Landaw EM, Wang D, Mazitschek R, Bradner JE, Sakamoto KM.
Leuk Lymphoma. 2011 Aug;52(8):1544-55.
Ribosomal protein L11 mutation in zebrafish leads to haematopoietic and metabolic defects.
Danilova N, Sakamoto KM, Lin S.
Br J Haematol. 2011 Jan;152(2):217-28.
Increasing diversity in pediatric hematology/oncology.
Frugé E, Lakoski JM, Luban N, Lipton JM, Poplack DG, Hagey A, Felgenhauer J, Hilden J, Margolin J, Vaiselbuh SR, Sakamoto KM.
Pediatr Blood Cancer. 2011 Jan 31. doi: 10.1002/pbc.22977. [Epub ahead of print] No abstract available.
PMID: 21284078 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/21284078
The multi-targeted receptor tyrosine kinase inhibitor, Linifanib (ABT-869), induces apoptosis through an AKT and Glycogen Synthase Kinase 3{beta}-dependent pathway.
Hernandez-Davies JE, Zape JP, Landaw EM, Tan X, Presnell A, Griffith DJ, Heinrich MC, Glaser KB, Sakamoto KM.
Mol Cancer Ther. 2011 Apr 6. [Epub ahead of print]
|
2010Publications
Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926.
Lin TL, Wang QH, Brown P, Peacock C, Merchant AA, Brennan S, Jones E, McGovern K, Watkins DN, Sakamoto KM, Matsui W.
PLoS One. 2010 Dec 28;5(12):e15262.
Ribosomal protein L11 mutation in zebrafish leads to haematopoietic and metabolic defects.
Danilova N, Sakamoto KM, Lin S.
Br J Haematol. 2011 Jan;152(2):217-28. doi: 10.1111/j.1365-2141.2010.08396.x. Epub 2010 Nov 29.
The role of the transcription factor CREB in immune function.
Wen AY, Sakamoto KM, Miller LS.
J Immunol. 2010 Dec 1;185(11):6413-9. Review.
The role of HDAC6 in cancer.
Aldana-Masangkay GI, Sakamoto KM.
J Biomed Biotechnol. 2011;2011:875824. Epub 2010 Nov 7.
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia.
Niemeyer CM, Kang MW, Shin DH, Furlan I, Erlacher M, Bunin NJ, Bunda S, Finklestein JZ, Sakamoto KM, Gorr TA, Mehta P, Schmid I, Kropshofer G, Corbacioglu S, Lang PJ, Klein C, Schlegel PG, Heinzmann A, Schneider M, Starý J, van den Heuvel-Eibrink MM, Hasle H, Locatelli F, Sakai D, Archambeault S, Chen L, Russell RC, Sybingco SS, Ohh M, Braun BS, Flotho C, Loh ML.
Nat Genet. 2010 Sep;42(9):794-800. Epub 2010 Aug 8.
Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy.
Wu WK, Sakamoto KM, Milani M, Aldana-Masankgay G, Fan D, Wu K, Lee CW, Cho CH, Yu J, Sung JJ.
Drug Resist Updat. 2010 Jun;13(3):87-92
Targeting CREB for cancer therapy: friend or foe.
Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM.
Curr Cancer Drug Targets. 2010 Jun;10(4):384-91.
ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.
Ikeda AK, Judelson DR, Federman N, Glaser KB, Landaw EM, Denny CT, Sakamoto KM.
Mol Cancer Ther. 2010 Mar;9(3):653-60. Epub 2010 Mar 2.
Protacs for treatment of cancer.
Sakamoto KM.
Pediatr Res. 2010 May;67(5):505-8.
|
2008Publications
Cheng JC, Kinjo K, Wu WS, Schmid I, Shankar DB, Stripecke R, Kasahara N, Bhatia R, Landaw EM, and KM Sakamoto. CREB is a critical regulator of normal hematopoiesis and leukemogenesis, Blood, 111: 1182-1192, 2008.
Danilova N, Sakamoto KM, and S Lin. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood, Epub May 30, 112(13):5228-37, 2008.
Pellegrini M, Cheng JC, Voutila J, Judelson D, Taylor JA, Nelson SF, and KM Sakamoto. Expression Profile of CREB knockdown in Myeloid Leukemia Cells. BMC Cancer, 18;8:264, 2008 [Epub].
Rodriguez-Gonzalez A, Cyrus K, Salcius M, Kim KB, Crews CM, Deshaies RJ, and KM Sakamoto. Targeting Steroid Hormone Receptors for Ubiquitination and Degradation in Breast and Prostate Cancer, Oncogene, 27:7201-11, 2008.
|
2007Publications
Shankar DB, Li J, Tapang P, McCall JO, Pease LJ, Dai Y, Wei RQ, Albert DH, Hartandi K, Michaelides M, Davidsen SK, Priceman S, Chang J, Shah N, Moore TB, Sakamoto KM*, and KB Glaser. ABT-869 a Multi-Targeted Receptor Tyrosine Kinase Inhibitor: Inhibition of FLT3 Phosphorylation and Signaling in AML, Blood, 109(8):3400-8, 2007. (*co-senior author)
Esparza S, Chang J, Shankar D, Zhang B, Nelson S, and KM Sakamoto. CREB regulates Meis1 Expression in Normal and Malignant Hematopoietic Cells, Leukemia, Sept. 6, 2007.
|
2005Publications
Shankar D, Cheng JC, Kinjo K, Wang J, Federman N, Moore TB, Gill A, Rao N, Landaw EM, and KM Sakamoto. The role of CREB as a proto-oncogene in Hematopoiesis and in Acute Myeloid Leukemia. Cancer Cell, 7:351-362, 2005.
Sakamoto KM. Chimeric Molecules to Target Proteins for Ubiquitination and Degradation. Methods in Enzymology (Ubiquitin and Proteasome System) 299C: 833-837, 2005.
|
2004Publications
Verma R, Peters NR, D'Onofrio, Tochtrop G, Sakamoto KM, Varada R, Fushman D, Deshaies RJ, and RW King. Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain. Science, 306:117-120, 2004.
Cheng JC and KM Sakamoto. The Emerging Role of RNA Interference in the Design of Novel Therapeutics in Oncology, Cell Cycle, 15: 3-13, 2004.
|
2001Publications
Shou W, Sakamoto KM, Keener J, Morimoto KW, Hoppe GJ, Azzam R, Traverso EE, Feldman RFR, DeModena J, Charbonneau H, Moazed D, Nomura M and RJ Deshaies. RENT complex stimulates RNA Pol I transcription and regulates nucleolar structure independently of controlling mitotic exit. Mol Cell, 8: 45-55, 2001.
Sakamoto KM, Crews CC, Kim KB, Kumagai A, Mercurio F, and RJ Deshaies. Protac: A Chimeric Molecule that targets Proteins to the SCF for Ubiquitination and Degradation. Proc Natl Acad Sci USA, 98: 8554-8559, 2001. |
1991 - 1995Publications
Sakamoto KM, Fraser JK, Lee H-J J, Lehman E, Gasson JC: GM-CSF and IL-3 signaling pathways converge on the CREB-binding site in the human EGR-1 promoter. Mol Cell Biol, 14: 5920-5928, 1994.
Lee H-J J, Mignacca RM, and KM Sakamoto. Transcriptional activation of egr-1 by Granulocyte-Macrophage Colony-Stimulating Factor but not Interleukin-3 requires phosphorylation of CREB on Serine 133. J. Biol. Chem., 270: 15979-15983, 1995.
Wong A and KM Sakamoto. GM-CSF-Induces the Transcriptional Activation of Egr-1 Through a Protein Kinase A-Independent Signaling Pathway. J Biol Chem 270: 30271-30273, 1995.
|
|
|
|
|
